Novo Nordisk (NVO) stock popped early Thursday after the company reported better-than-expected third-quarter sales and a massive jump in earnings.


For the September quarter, Novo’s sales climbed 29% to 58.73 billion Danish krone, or roughly $8.39 billion, based on today’s exchange rates. That topped the FactSet-polled analyst view for 57.88 billion Danish krone.

Adjusted profit came out 5.02 Danish krone per share — about 72 cents a share. Earnings grew 57% and topped expectations for 4.70 Danish krone.

Sales of weight-loss blockbuster Wegovy skyrocketed 734% to 9.65 Danish krone, or $1.38 billion. That came in well above expectations for 7.72 billion Danish krone. Revenue from diabetes injection Ozempic — which uses the same active ingredient as Wegovy — brought in 23.91 billion Danish krone, or $3.42 billion. Ozempic sales grew 46%, but lagged views for 24.34 billion Danish krone.

For the year, the drugmaker reiterated its guidance for 32% to 38% sales growth and 40% to 46% growth in operating profit, in constant currency.

In premarket trades on today’s stock market, Novo Nordisk stock jumped 3.6% near 101.20. Shares have a strong IBD Digital Relative Strength Rating of 97 on a 1-99 scale of a stock’s 12-month performance.

More to follow.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.


Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug

GSK Dives As Shingrix Comes In Light Despite Strong RSV Vaccine Launch

Watch IBD’s Investing Strategies Show For Actionable Market Insights

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Find Winning Stocks With MarketSmith Pattern Recognition & Custom Screens


Please enter your comment!
Please enter your name here